Redox proteomics in selected neurodegenerative disorders: From its infancy to future applications

Antioxidants and Redox Signaling

Volumn 17, Issue 11, 2012, Pages 1610-1655

  Butterfield, D Allan ^a   Perluigi, Marzia ^b   Reed, Tanea ^c   Muharib, Tasneem ^d   Hughes, Christopher P ^d   Robinson, Renã A S ^d   Sultana, Rukhsana ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c EASTERN KENTUCKY UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CARBONYL DERIVATIVE; CATALASE; GLUTATHIONE REDUCTASE; HYDROLASE; IRON; NITROGEN DIOXIDE; PARKIN; PEROXIREDOXIN; PEROXYNITRITE; PROTEASOME; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TAU PROTEIN; THIOREDOXIN REDUCTASE; UBIQUITIN; UBIQUITIN THIOLESTERASE; VITAMIN;

ALZHEIMER DISEASE; AMNESIA; AMYOTROPHIC LATERAL SCLEROSIS; CARBONYLATION; CELL CYCLE REGULATION; CHEMICAL ANALYSIS; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DETOXIFICATION; DISEASE COURSE; DOWN SYNDROME; EXCITOTOXICITY; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; LIPID OXIDATION; LONG TERM POTENTIATION; MITOCHONDRION; NERVE DEGENERATION; NEURITE; NEURITIS; NITRATION; NONHUMAN; OXIDATION KINETICS; OXIDATION REDUCTION REACTION; PATHOGENESIS; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CARBONYLATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SYNAPSE;

ALDEHYDES; HUMANS; IRON; LIPID PEROXIDATION; METABOLIC DETOXICATION, PHASE I; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; PROTEOMICS; REACTIVE NITROGEN SPECIES;

ANIMALIA;

EID: 84866862372     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4109     Document Type: Review

References (412)

1. Abboud K, Bassila JC, Ghali-Ghoul R, and Sabra R. Temporal changes in vascular reactivity in early diabetes mellitus in rats: role of changes in endothelial factors and in phosphodiesterase activity. Am J Physiol Heart Circ Physiol 297: H836-H845, 2009.
2. Abe K, Pan LH, Watanabe M, Kato T, and Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett 199: 152-154, 1995.
3. Abe K, Pan LH, Watanabe M, Konno H, Kato T, and Itoyama Y. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol Res 19: 124-128, 1997. (Pubitemid 27190700)
4. Abello N, Barroso B, Kerstjens HA, Postma DS, and Bischoff R. Chemical labeling and enrichment of nitrotyrosinecontaining peptides. Talanta 80: 1503-1512, 2010.
5. Adibhatla RM and Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 12: 125-169, 2010.
6. Aksenov M, Aksenova M, Butterfield DA, and Markesbery WR. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem 74: 2520-2527, 2000. (Pubitemid 30314229)
7. Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, and Markesbery WR. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J Mol Neurosci 11: 151-164, 1998. (Pubitemid 29140165)
8. Aksenova MV and Burbaeva G. [BB creatine kinase isoenzyme activity in the blood serum of patients with senile dementia, Alzheimer's disease and schizophrenia]. Zh Nevropatol Psikhiatr Im S S Korsakova 89: 113-116, 1989. (Pubitemid 19243331)
9. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, and Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-1203, 1997. (Pubitemid 27364841)
10. Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, and Butterfield DA. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J Alzheimers Dis 23: 257-269, 2011.
11. Alvarez B and Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25: 295-311, 2003. (Pubitemid 38041267)
12. Andersen JK. Iron dysregulation and Parkinson's disease. J Alzheimers Dis 6: S47-S52, 2004. (Pubitemid 40202542)
13. Andersen PM. Genetic factors in the early diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 1 Suppl 1: S31-S42, 2000.
14. Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, and Beal MF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 8: 479-491, 2001. (Pubitemid 32566138)
15. Andrus PK, Fleck TJ, Gurney ME, and Hall ED. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 71: 2041-2048, 1998. (Pubitemid 28491560)
16. Anilkumar N, Parsons M, Monk R, Ng T, and Adams JC. Interaction of fascin and protein kinase C alpha: a novel intersection in cell adhesion and motility. EMBO J 22: 5390-5402, 2003. (Pubitemid 37279949)
17. Ansari MA, Joshi G, Huang Q, Opii WO, Abdul HM, Sultana R, and Butterfield DA. In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer's disease and other oxidative stressrelated neurodegenerative disorders. Free Radic Biol Med 41: 1694-1703, 2006. (Pubitemid 44634240)
18. Ansari MA and Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 69: 155-167, 2010.
19. Arbuzova S, Hutchin T, and Cuckle H. Mitochondrial dysfunction and Down's syndrome. Bioessays 24: 681-684, 2002. (Pubitemid 34850322)
20. Arendt T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the "Dr. Jekyll and Mr. Hyde concept" of Alzheimer's disease or the yin and yang of neuroplasticity. Prog Neurobiol 71: 83-248, 2003. (Pubitemid 38004483)
21. Arima K, Ogawa M, Sunohara N, Nishio T, Shimomura Y, Hirai S, and Eto K. Immunohistochemical and ultrastructural characterization of ubiquitinated eosinophilic fibrillary neuronal inclusions in sporadic amyotrophic lateral sclerosis. Acta Neuropathol 96: 75-85, 1998. (Pubitemid 28297851)
22. Aulak KS, Koeck T, Crabb JW, and Stuehr DJ. Proteomic method for identification of tyrosine-nitrated proteins. Methods Mol Biol 279: 151-165, 2004.
23. Bader Lange ML, Cenini G, Piroddi M, Abdul HM, Sultana R, Galli F, Memo M, and Butterfield DA. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis 29: 456-464, 2008.
24. Bader Lange ML, St. Clair D, Markesbery WR, Studzinski CM, Murphy MP, and Butterfield DA. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol Dis 38: 104-115, 2010.
25. Baillet A, Chanteperdrix V, Trocme C, Casez P, Garrel C, and Besson G. The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem Res 35: 1530-1537, 2010.
26. Balcz B, Kirchner L, Cairns N, Fountoulakis M, and Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl (61): 193-201, 2001. (Pubitemid 38085082)
27. Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, and Oliveira CR. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 15: 117-128, 2008.
28. Baloyannis SJ, Costa V, Mauroudis I, Psaroulis D, Manolides SL, and Manolides LS. Dendritic and spinal pathology in the acoustic cortex in Alzheimer's disease: morphological and morphometric estimation by Golgi technique and electron microscopy. Acta Otolaryngol 127: 351-354, 2007. (Pubitemid 46572867)
29. Barber SC and Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48: 629-641, 2010.
30. Bartels T, Choi JG, and Selkoe DJ. Alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477: 107-110, 2011.
31. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, and Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4: 3943-3952, 2004. (Pubitemid 39657469)
32. Basso M, Samengo G, Nardo G, Massignan T, D'Alessandro G, Tartari S, Cantoni L, Marino M, Cheroni C, De Biasi S, Giordana MT, Strong MJ, Estevez AG, Salmona M, Bendotti C, and Bonetto V. Characterization of detergentinsoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One 4: e8130, 2009.
33. Battaini F, Pascale A, Lucchi L, Pasinetti GM, and Govoni S. Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Exp Neurol 159: 559-564, 1999. (Pubitemid 29485243)
34. Baty JW, Hampton MB, and Winterbourn CC. Detection of oxidant sensitive thiol proteins by fluorescence labeling and two-dimensional electrophoresis. Proteomics 2: 1261-1266, 2002.
35. Bayir H, Kagan VE, Clark RS, Janesko-Feldman K, Rafikov R, Huang Z, Zhang X, Vagni V, Billiar TR, and Kochanek PM. Neuronal NOS-mediated nitration and inactivation of manganese superoxide dismutase in brain after experimental and human brain injury. J Neurochem 101: 168-181, 2007. (Pubitemid 46426473)
36. Beal MF and Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 5: 373-384, 2004. (Pubitemid 38568498)
37. Beasley A, Anderson C, McArthur J, Sacktor N, Nath A, and Cotter JR. Characterization of nitrotyrosine-modified proteins in cerebrospinal fluid. Clin Proteomics 6: 29-41, 2010.
38. Beckman JS, Chen J, Crow JP, and Ye YZ. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 103: 371-380, 1994.
39. Berg D and Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 17: 5-17, 2006. (Pubitemid 46672929)
40. Berlett BS and Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272: 20313-20316, 1997. (Pubitemid 27355575)
41. Bigl M, Bruckner MK, Arendt T, Bigl V, and Eschrich K. Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Trans 106: 499-511, 1999. (Pubitemid 29273888)
42. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, and Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 79: 1246-1249, 2001. (Pubitemid 34019802)
43. Bogdanovic N, Zilmer M, Zilmer K, Rehema A, and Karelson E. The Swedish APP670/671 Alzheimer's disease mutation: the first evidence for strikingly increased oxidative injury in the temporal inferior cortex. Dement Geriatr Cogn Disord 12: 364-370, 2001. (Pubitemid 34701659)
44. Bommer UA, Borovjagin AV, Greagg MA, Jeffrey IW, Russell P, Laing KG, Lee M, and Clemens MJ. The mRNA of the translationally controlled tumor protein P23/TCTP is a highly structured RNA, which activates the dsRNA-dependent protein kinase PKR. RNA 8: 478-496, 2002. (Pubitemid 34437718)
45. Bonilla E, Estevez J, Suarez H, Morales LM, Chacin de Bonilla L, Villalobos R, and Davila JO. Serum ferritin deficiency in Huntington's disease patients. Neurosci Lett 129: 22-24, 1991.
46. Bonini NM and Giasson BI. Snaring the function of alphasynuclein. Cell 123: 359-361, 2005.
47. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, Goolsby H, Fontaine BA, Lemay N, McKenna-Yasek D, Frosch MP, Agar JN, Julien JP, Brady ST, and Brown RH, Jr. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 13: 1396-1403, 2010.
48. Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, Murri L, Rapoport SI, and Solaini G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 23: 371-376, 2002. (Pubitemid 34312019)
49. Bowling AC, Schulz JB, Brown RH, Jr., and Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61: 2322-2325, 1993. (Pubitemid 23354097)
50. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, and Butterfield DA. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 1044: 206-215, 2005. (Pubitemid 40693453)
51. Bradley MA, Markesbery WR, and Lovell MA. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med 48: 1570-1576, 2010.
52. Browne SE. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci 1147: 358-382, 2008.
53. Browne SE and Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 8: 2061-2073, 2006. (Pubitemid 46489631)
54. Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH, Jr., and Beal MF. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem 71: 281-287, 1998. (Pubitemid 28292560)
55. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, and Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41: 646-653, 1997. (Pubitemid 27212659)
56. Browne SE, Ferrante RJ, and Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 9: 147-163, 1999. (Pubitemid 29056525)
57. Bruening W, Roy J,Giasson B, FiglewiczDA,MushynskiWE, and Durham HD. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem 72: 693-699, 1999. (Pubitemid 29055232)
58. Bubber P, Haroutunian V, Fisch G, Blass JP, and Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57: 695-703, 2005. (Pubitemid 40628858)
59. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, and Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95-130, 2000.
60. Burkhard PR, Sanchez JC, Landis T, and Hochstrasser DF. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 56: 1528-1533, 2001. (Pubitemid 32532265)
61. Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, and Yankner BA. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33: 677-688, 2002. (Pubitemid 34219240)
62. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, and Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem 13: 444, 2002.
63. Butterfield DA. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10: 495-506, 1997. (Pubitemid 27217205)
64. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, and Martins RN. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: An initial assessment. J Alzheimers Dis 10: 391-397, 2006.
65. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, and Sultana R. Pin1 in Alzheimer's disease. J Neurochem 98: 1697-1706, 2006. (Pubitemid 44298238)
66. Butterfield DA, Bader Lange ML, and Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 1801: 924-929, 2010.
67. Butterfield DA and Boyd-Kimball D. The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703: 149-156, 2005. (Pubitemid 40170438)
68. Butterfield DA and Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids 25: 419-425, 2003. (Pubitemid 38041276)
69. Butterfield DA, Drake J, Pocernich C, and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7: 548-554, 2001. (Pubitemid 33127140)
70. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, and Bredesen DE. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48: 136-144, 2010.
71. Butterfield DA, Hardas SS, and Lange ML. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration. J Alzheimers Dis 20: 369-393, 2010.
72. Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, Bummer PM, Haley BE, and Carney JM. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem 68: 2451-2457, 1997. (Pubitemid 27218166)
73. Butterfield DA and Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 111: 915-933, 2009.
74. Butterfield DA and Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid betapeptide-associated free radical oxidative stress. Free Radic Biol Med 32: 1050-1060, 2002. (Pubitemid 34603342)
75. Butterfield DA, Perluigi M, and Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 545: 39-50, 2006. (Pubitemid 44215876)
76. Butterfield DA, Poon HF, St. Clair D, Keller JN, Pierce WM, Klein JB, and Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22: 223-232, 2006.
77. Butterfield DA, Reed T, Newman SF, and Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43: 658-677, 2007. (Pubitemid 47102132)
78. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, and Sultana R. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397: 170-173, 2006.
79. Butterfield DA and Stadtman ER. Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 2: 161-191, 1997.
80. Butterfield DA and Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 12: 61-72, 2007. (Pubitemid 47396301)
81. Calabrese V. Highlight Commentary on Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 43: 160-162, 2007. (Pubitemid 46977162)
82. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, and Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 8: 766-775, 2007. (Pubitemid 47462116)
83. Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, Galli F, and Butterfield DA. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25: 437-444, 2003. (Pubitemid 38041278)
84. Calabrese V, Scapagnini G, Ravagna A, Colombrita C, Spadaro F, Butterfield DA, and Giuffrida Stella AM. Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech Ageing Dev 125: 325-335, 2004. (Pubitemid 38438512)
85. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, and Cookson MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101: 9103-9108, 2004. (Pubitemid 38781618)
86. Caperna TJ, Shannon AE, Blomberg le A, Garrett WM, and Ramsay TG. Identification of protein carbonyls in serum of the fetal and neonatal pig. Comp Biochem Physiol B Biochem Mol Biol 156: 189-196, 2010.
87. Casado A, Encarnacion Lopez-Fernandez M, Concepcion Casado M, and de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 33: 450-458, 2008. (Pubitemid 351230446)
88. Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A, and Ghezzi P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci USA 99: 9745-9749, 2002. (Pubitemid 34831118)
89. Casoni F, Basso M, Massignan T, Gianazza E, Cheroni C, Salmona M, Bendotti C, and Bonetto V. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem 280: 16295-16304, 2005. (Pubitemid 40616757)
90. Cassina AM, Hodara R, Souza JM, Thomson L, Castro L, Ischiropoulos H, Freeman BA, and Radi R. Cytochrome c nitration by peroxynitrite. J Biol Chem 275: 21409-21415, 2000. (Pubitemid 30481842)
91. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, and Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33: 562-571, 2002. (Pubitemid 34874977)
92. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, and Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82: 1524-1532, 2002.
93. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, and Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85: 1394-1401, 2003. (Pubitemid 36702552)
94. Caudle WM, Pan S, Shi M, Quinn T, Hoekstra J, Beyer RP, Montine TJ, and Zhang J. Proteomic identification of proteins in the human brain: towards a more comprehensive understanding of neurodegenerative disease. Proteomics Clin Appl 2: 1484-1497, 2008.
95. Cenini G, Dowling ALS, Beckett T, Barone E, Mancuso C, Murphy MP, Levine III H, Schmitt FA, Butterfield DA, and Head E. Association between frontal cortex oxidative damage and beta-amyloid neuropathology as a function of age in Down syndrome. Biochem Biophys Acta 1822: 130-138, 2011.
96. Charkoudian LK and Franz KJ. Fe(III)-coordination properties of neuromelanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2- carboxylic acid. Inorg Chem 45: 3657-3664, 2006.
97. Chavez J, Chung WG, Miranda CL, Singhal M, Stevens JF, and Maier CS. Site-specific protein adducts of 4-hydroxy-2(E)-nonenal in human THP-1 monocytic cells: protein carbonylation is diminished by ascorbic acid. Chem Res Toxicol 23: 37-47, 2010.
98. Chavez J, Wu J, Han B, Chung WG, and Maier CS. New role for an old probe: affinity labeling of oxylipid protein conjugates by N'- aminooxymethylcarbonylhydrazino dbiotin. Anal Chem 78: 6847-6854, 2006. (Pubitemid 44522535)
99. Chen Q, Surmeier DJ, and Reiner A. NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. Exp Neurol 159: 283-296, 1999. (Pubitemid 29444925)
100. Chen ZH, Saito Y, Yoshida Y, Sekine A, Noguchi N, and Niki E. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J Biol Chem 280: 41921-41927, 2005. (Pubitemid 43023161)
101. Chiappetta G, Corbo C, Palmese A, Galli F, Piroddi M, Marino G, and Amoresano A. Quantitative identification of protein nitration sites. Proteomics 9: 1524-1537, 2009.
102. Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, Na KR, Kim SY, Shin YT, and Lee KW. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol 297: F362-F370, 2009.
103. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, and Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279: 13256-13264, 2004. (Pubitemid 38445905)
104. Cimini A, Moreno S, D'Amelio M, Cristiano L, D'Angelo B, Falone S, Benedetti E, Carrara P, Fanelli F, Cecconi F, Amicarelli F, and Ceru MP. Early biochemical and morphological modifications in the brain of a transgenic mouse model of Alzheimer's disease: a role for peroxisomes. J Alzheimers Dis 18: 935-952, 2009.
105. Clementi ME, Pezzotti M, Orsini F, Sampaolese B, Mezzogori D, Grassi C, Giardina B, and Misiti F. Alzheimer's amyloid beta-peptide (1-42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem Biophys Res Commun 342: 206-213, 2006. (Pubitemid 43247378)
106. Cleveland DW and Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2: 806-819, 2001. (Pubitemid 33674062)
107. Coleman PD and Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 8: 521-545, 1987. (Pubitemid 18006178)
108. Connor JR, Snyder BS, Beard JL, Fine RE, and Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 31: 327-335, 1992.
109. Crichton RR and Pierre JL. Old iron, young copper: from Mars to Venus. Biometals 14: 99-112, 2001. (Pubitemid 32656569)
110. Cruthirds DL, Novak L, Akhi KM, Sanders PW, Thompson JA, and MacMillan-Crow LA. Mitochondrial targets of oxidative stress during renal ischemia/reperfusion. Arch Biochem Biophys 412: 27-33, 2003. (Pubitemid 36324361)
111. Curti D, Malaspina A, Facchetti G, Camana C, Mazzini L, Tosca P, Zerbi F, and Ceroni M. Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology 47: 1060-1064, 1996.
112. D'Alessandro A, Rinalducci S, and Zolla L. Redox proteomics and drug development. J Proteomics 74: 2575-2595, 2011.
113. Dalle-Donne I. Familial amyotrophic lateral sclerosis (FALS): Emerging hints from redox proteomics. Highlight commentary on: "Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis". Free Radic Biol Med 43: 157-159, 2007. (Pubitemid 46977158)
114. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, and Milzani A. Protein carbonylation in human diseases. Trends Mol Med 9: 169-176, 2003. (Pubitemid 36626706)
115. Dalle-Donne I, Scaloni A, and Butterfield DA. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases. Hoboken, NJ: John Wiley and Sons, 2006.
116. Daly NL, Hoffmann R, Otvos L, Jr., and Craik DJ. Role of phosphorylation in the conformation of tau peptides implicated in Alzheimer's disease. Biochemistry 39: 9039-9046, 2000. (Pubitemid 30602815)
117. David S, Shoemaker M, and Haley BE. Abnormal properties of creatine kinase in Alzheimer's disease brain: correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Brain Res Mol Brain Res 54: 276-287, 1998. (Pubitemid 28171792)
118. Davies KJ and Shringarpure R. Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases. Neurology 66: S93-S96, 2006. (Pubitemid 43739992)
119. Davies P, Moualla D, and Brown DR. Alpha-synuclein is a cellular ferrireductase. PLoS One 6: e15814, 2011.
120. De Iuliis A, Grigoletto J, Recchia A, Giusti P, and Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin Chim Acta 357: 202-209, 2005. (Pubitemid 40894638)
121. Demicheli V, Quijano C, Alvarez B, and Radi R. Inactivation and nitration of human superoxide dismutase (SOD) by fluxes of nitric oxide and superoxide. Free Radic Biol Med 42: 1359-1368, 2007. (Pubitemid 46467271)
122. Dexter DT, Jenner P, Schapira AH, and Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 Suppl: S94-S100, 1992.
123. Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C, and Butterfield DA. Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 1333: 72-81, 2010.
124. Di Stasi AM, Mallozzi C, Macchia G, Petrucci TC, and Minetti M. Peroxynitrite induces tryosine nitration and modulates tyrosine phosphorylation of synaptic proteins. J Neurochem 73: 727-735, 1999. (Pubitemid 29339847)
125. Diamandis EP and Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 37: 625-636, 1991. (Pubitemid 21892699)
126. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, and Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993, 1997. (Pubitemid 27449140)
127. Ding B, Chen KM, Ling HW, Sun F, Li X, Wan T, Chai WM, Zhang H, Zhan Y, and Guan YJ. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J Magn Reson Imaging 29: 793-798, 2009.
128. DingQ,MarkesberyWR, Cecarini V, andKeller JN.Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res 31: 705-710, 2006. (Pubitemid 43886420)
129. Doorn JA, Maser E, Blum A, Claffey DJ, and Petersen DR. Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry 43: 13106-13114, 2004. (Pubitemid 39366059)
130. Doorn JA and Petersen DR. Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal. Chem Biol Interact 143-144: 93-100, 2003. (Pubitemid 36246435)
131. Drake J, Link CD, and Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24: 415-420, 2003. (Pubitemid 36210870)
132. Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, and Seiden MV. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22: 1933-1941, 2002. (Pubitemid 34857007)
133. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, and Bush AI. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142: 857-867, 2010.
134. Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, and Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 23: 2459-2466, 2009.
135. Duyckaerts C, Delatour B, and Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118: 5-36, 2009.
136. Eismann T, Huber N, Shin T, Kuboki S, Galloway E, Wyder M, Edwards MJ, Greis KD, Shertzer HG, Fisher AB, and Lentsch AB. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemiareperfusion in mice. Am J Physiol Gastrointest Liver Physiol 296: G266-G274, 2009.
137. El Tannir El Tayara N, Delatour B, Le Cudennec C, Guegan M, Volk A, and Dhenain M. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 22: 199-208, 2006.
138. Eliuk SM, Renfrow MB, Shonsey EM, Barnes S, and Kim H. Active site modifications of the brain isoform of creatine kinase by 4-hydroxy-2-nonenal correlate with reduced enzyme activity: mapping of modified sites by Fourier transform-ion cyclotron resonance mass spectrometry. Chem Res Toxicol 20: 1260-1268, 2007. (Pubitemid 47548294)
139. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128, 1991. (Pubitemid 121003917)
140. Estevez AG. Good science shows the way. Highlight Commentary on "Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis". Free Radic Biol Med 43: 163-164, 2007. (Pubitemid 46977160)
141. Fagni L and Bockaert J. Effects of nitric oxide on glutamategated channels and other ionic channels. J Chem Neuroanat 10: 231-240, 1996. (Pubitemid 26196650)
142. Fan Q, Yang XC, Cao XB, Wang SY, Yang SL, Liu XL, and Gao F. Glutathione reverses peroxynitrite-mediated deleterious effects of nitroglycerin on ischemic rat hearts. J Cardiovasc Pharmacol 47: 405-412, 2006. (Pubitemid 44309694)
143. Faucheux BA, Martin ME, Beaumont C, Hunot S, Hauw JJ, Agid Y, and Hirsch EC. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem 83: 320-330, 2002. (Pubitemid 35191397)
144. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH, Jr., and Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064-2074, 1997. (Pubitemid 27452754)
145. Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, Gurney ME, and Beal MF. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326-334, 1997. (Pubitemid 27391116)
146. Ferrer I. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease. Neuropathol Appl Neurobiol 28: 441-451, 2002. (Pubitemid 35425597)
147. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, and Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2: 3-18, 2005. (Pubitemid 41389255)
148. Ferrer I, Martinez A, Blanco R, Dalfo E, and Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 118: 821-839, 2011.
149. Filipovic MR, Stanic D, Raicevic S, Spasic M, and Niketic V. Consequences of MnSOD interactions with nitric oxide: nitric oxide dismutation and the generation of peroxynitrite and hydrogen peroxide. Free Radic Res 41: 62-72, 2007. (Pubitemid 44896875)
150. Fishman-Jacob T, Reznichenko L, Youdim MB, and Mandel SA. A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A. J Biol Chem 284: 32835-32845, 2009.
151. Fitzmaurice PS, Shaw IC, Kleiner HE, Miller RT, Monks TJ, Lau SS, Mitchell JD, and Lynch PG. Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve 19: 797-798, 1996.
152. Flint DH, Tuminello JF, and Emptage MH. The inactivation of Fe-S cluster containing hydro-lyases by superoxide. J Biol Chem 268: 22369-22376, 1993. (Pubitemid 23318282)
153. Floor E and Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70: 268-275, 1998. (Pubitemid 28020852)
154. Forrest GL and Gonzalez B. Carbonyl reductase. Chem Biol Interact 129: 21-40, 2000. (Pubitemid 32061052)
155. Foy CJ, Passmore AP, Vahidassr MD, Young IS, and Lawson JT. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 92: 39-45, 1999. (Pubitemid 29034099)
156. Francis PT, Palmer AM, Snape M, and Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147, 1999. (Pubitemid 29103513)
157. Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmona M, Bonetto V, Mengozzi M, Duffieux F, Miclet E, Bachi A, Vandekerckhove J, Gianazza E, and Ghezzi P. Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci USA 99: 3505-3510, 2002. (Pubitemid 34252138)
158. Frautschy SA, Baird A, and Cole GM. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci USA 88: 8362-8366, 1991. (Pubitemid 21915356)
159. Fucci L, Oliver CN, Coon MJ, and Stadtman ER. Inactivation of key metabolic enzymes by mixed-function oxidation reactions: possible implication in protein turnover and ageing. Proc Natl Acad Sci USA 80: 1521-1525, 1983. (Pubitemid 13052442)
160. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, and Konishi J. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med 35: 1-6, 1994. (Pubitemid 24018423)
161. Gabbita SP, Aksenov MY, Lovell MA, and Markesbery WR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem 73: 1660-1666, 1999. (Pubitemid 29440169)
162. Gadoni E, Olivero A, Miglietta A, Bocca C, and Gabriel L. Cytoskeletal modifications induced by 4-hydroxynonenal. Cytotechnology 11 Suppl 1: S62-S64, 1993.
163. Ganea E. Chaperone-like activity of alpha-crystallin and other small heat shock proteins. Curr Protein Pept Sci 2: 205-225, 2001. (Pubitemid 32798792)
164. Gardner PR, Nguyen DD, and White CW. Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs. Proc Natl Acad Sci USA 91: 12248-12252, 1994. (Pubitemid 24368642)
165. Geddes JW, Pang Z, and Wiley DH. Hippocampal damage and cytoskeletal disruption resulting from impaired energy metabolism. Implications for Alzheimer disease. Mol Chem Neuropathol 28: 65-74, 1996. (Pubitemid 26275052)
166. George AJ, Holsinger RM, McLean CA, Tan SS, Scott HS, Cardamone T, Cappai R, Masters CL, and Li QX. Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging 27: 614-623, 2006. (Pubitemid 43290530)
167. Giambattistelli F, Bucossi S, Salustri C, Panetta V, Mariani S, Siotto M, Ventriglia M, Vernieri F, Dell'acqua ML, Cassetta E, Rossini PM, and Squitti R. Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiol Aging in press, 2011.
168. Giasson BI, Ischiropoulos H, Lee VM, and Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 32: 1264-1275, 2002. (Pubitemid 34607630)
169. Giovannini MG, Cerbai F, Bellucci A, Melani C, Grossi C, Bartolozzi C, Nosi D, and Casamenti F. Differential activation of mitogen-activated protein kinase signalling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer's disease. Neuroscience 153: 618-633, 2008.
170. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27: 570-575, 2006. (Pubitemid 43290525)
171. Gokulrangan G, Zaidi A, Michaelis ML, and Schoneich C. Proteomic analysis of protein nitration in rat cerebellum: effect of biological aging. J Neurochem 100: 1494-1504, 2007. (Pubitemid 46376214)
172. Golej J, Hoeger H, Radner W, Unfried G, and Lubec G. Oral administration of methylglyoxal leads to kidney collagen accumulation in the mouse. Life Sci 63: 801-807, 1998. (Pubitemid 28383729)
173. Gomez A and Ferrer I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res 87: 1002-1013, 2009.
174. Goshima Y, Nakamura F, Strittmatter P, and Strittmatter SM. Collapsin-induced growth cone collapse mediated by an intracellular protein related to Unc-33. Nature 376: 509-514, 1995.
175. Gotz ME, Kunig G, Riederer P, and Youdim MB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37-122, 1994. (Pubitemid 24250150)
176. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, and Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-6089, 1986. (Pubitemid 17207447)
177. Gulesserian T, Seidl R, Hardmeier R, Cairns N, and Lubec G. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med 49: 41-46, 2001. (Pubitemid 32112582)
178. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 152 Suppl 1: S67-S73, 1997. (Pubitemid 27505293)
179. Hague SM, Klaffke S, and Bandmann O. Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry 76: 1058-1063, 2005. (Pubitemid 41081275)
180. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 97: 1634-1658, 2006. (Pubitemid 43873658)
181. Halliwell B. Proteasomal dysfunction: a common feature of neurodegenerative diseases? Implications for the environmental origins of neurodegeneration. Antioxid Redox Signal 8: 2007-2019, 2006. (Pubitemid 46489628)
182. Hand CK and Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve 25: 135-159, 2002. (Pubitemid 34117061)
183. Hara MR and Snyder SH. Nitric oxide-GAPDH-Siah: a novel cell death cascade. Cell Mol Neurobiol 26: 527-538, 2006.
184. Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, and Muller WE. Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp Gerontol 41: 668-673, 2006. (Pubitemid 43866354)
185. Hayes JP and Tipton KF. Interactions of the neurotoxin 6-hydroxydopamine with glyceraldehyde-3-phosphate dehydrogenase. Toxicol Lett 128: 197-206, 2002. (Pubitemid 34183462)
186. Healy DG, Abou-Sleiman PM, and Wood NW. Genetic causes of Parkinson's disease: UCHL-1. Cell Tissue Res 318: 189-194, 2004. (Pubitemid 39362639)
187. Hellberg K, Grimsrud PA, Kruse AC, Banaszak LJ, Ohlendorf DH, and Bernlohr DA. X-ray crystallographic analysis of adipocyte fatty acid binding protein (aP2) modified with 4-hydroxy-2-nonenal. Prot Sci 19: 1480-1489, 2010.
188. Helman M and Givol D. Isolation of nitrotyrosine-containing peptides by using an insoluble-antibody column. Biochem J 125: 971-974, 1971.
189. Hensley K, Fedynyshyn J, Ferrell S, Floyd RA, Gordon B, Grammas P, Hamdheydari L, Mhatre M, Mou S, Pye QN, Stewart C, West M, West S, and Williamson KS. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14: 74-80, 2003. (Pubitemid 37103181)
190. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65: 2146-2156, 1995.
191. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, and MacDonald ME. Huntingtin: an ironregulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 9: 2789-2797, 2000.
192. Hillmer AS, Putcha P, Levin J, Hogen T, Hyman BT, Kretzschmar H, McLean PJ, and Giese A. Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun 391: 461-466, 2010.
193. Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A, Mollnau H, August M, Baldus S, Tsilimingas N, Walter U, Ullrich V, and Munzel T. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol 42: 1826-1834, 2003. (Pubitemid 37433665)
194. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, and Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017-3023, 2001. (Pubitemid 32323483)
195. Hirano M, Quinzii CM, Mitsumoto H, Hays AP, Kirk Roberts J, Richard P, and Rowland LP. Senataxin mutations and amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12: 223-227, 2010.
196. Holzer M, Gartner U, Stobe A, Hartig W, Gruschka H, Bruckner MK, and Arendt T. Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathol 104: 471-481, 2002. (Pubitemid 36075415)
197. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 35: 1363-1372, 2000.
198. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490: 115-125, 2004. (Pubitemid 38482165)
199. Hsu JL, Chen SH, Li DT, and Shi FK. Enhanced a1 fragmentation for dimethylated proteins and its applications for N-terminal identification and comparative protein quantitation. J Proteome Res 6: 2376-2383, 2007.
200. Huang LL, Shang F, Nowell TR, Jr., and Taylor A. Degradation of differentially oxidized alpha-crystallins in bovine lens epithelial cells. Exp Eye Res 61: 45-54, 1995.
201. Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Ferrante K, Newhall K, Jennings D, Kelsey T, Walker F, Hunt V, Daigneault S, Goldstein M, Weber J, Watts A, Beal MF, Browne SE, and Metakis LJ. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord 25: 1924-1928, 2010.
202. Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, An Y, West MJ, Crain B, and Troncoso JC. Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol 67: 578-589, 2008. (Pubitemid 351787084)
203. Iannello RC, Crack PJ, de Haan JB, and Kola I. Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm Suppl 57: 257-267, 1999.
204. Ignarro LJ. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 16: 477-483, 1990. (Pubitemid 20368334)
205. Ihara Y, Nobukuni K, Takata H, and Hayabara T. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res 27: 105-108, 2005. (Pubitemid 40189615)
206. Ince PG, Shaw PJ, Candy JM, Mantle D, Tandon L, Ehmann WD, and Markesbery WR. Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci Lett 182: 87-90, 1994. (Pubitemid 24362029)
207. Ishihara K, Amano K, Takaki E, Ebrahim AS, Shimohata A, Shibazaki N, Inoue I, Takaki M, Ueda Y, Sago H, Epstein CJ, and Yamakawa K. Increased lipid peroxidation in Down's syndrome mouse models. J Neurochem 110: 1965-1976, 2009.
208. Jang BG, Yun SM, Ahn K, Song JH, Jo SA, Kim YY, Kim DK, Park MH, Han C, and Koh YH. Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease. J Alzheimers Dis JAD 21: 939-945, 2010.
209. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3: S26-S36, 2003; discussion S36-S38.
210. Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, and David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci 29: 610-619, 2009.
211. Jiang H, Luan Z, Wang J, and Xie J. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int 49: 605-609, 2006. (Pubitemid 44528090)
212. Joguchi A, Otsuka I, Minagawa S, Suzuki T, Fujii M, and Ayusawa D. Overexpression of VDUP1 mRNA sensitizes HeLa cells to paraquat. Biochem Biophys Res Commun 293: 293-297, 2002. (Pubitemid 34694205)
213. Jouvenceau A, Dutar P, and Billard JM. Alteration of NMDA receptor-mediated synaptic responses in CA1 area of the aged rat hippocampus: contribution of GABAergic and cholinergic deficits. Hippocampus 8: 627-637, 1998. (Pubitemid 29010190)
214. Jovanovic SV, Clements D, and MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 25: 1044-1048, 1998. (Pubitemid 28558330)
215. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, and Haass C. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159: 2215-2225, 2001. (Pubitemid 33104275)
216. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, and Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis 15: 473-493, 2008.
217. Kanski J, Alterman MA, and Schoneich C. Proteomic identification of age-dependent protein nitration in rat skeletal muscle. Free Radic Biol Med 35: 1229-1239, 2003. (Pubitemid 37357248)
218. Kanski J, Hong SJ, and Schoneich C. Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine- containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem 280: 24261-24266, 2005. (Pubitemid 40884916)
219. Kapogiannis D and Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol 10: 187-198, 2011.
220. Kato S, Hayashi H, Nakashima K, Nanba E, Kato M, Hirano A, Nakano I, Asayama K, and Ohama E. Pathological characterization of astrocytic hyaline inclusions in familial amyotrophic lateral sclerosis. Am J Pathol 151: 611-620, 1997. (Pubitemid 27330081)
221. Keller JN, Hanni KB, and Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 75: 436-439, 2000. (Pubitemid 30418211)
222. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, and Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64: 1152-1156, 2005.
223. Kida K, Nishio T, Nagai K, Matsuda H, and Nakagawa H. Gluconeogenesis in the kidney in vivo in fed rats. Circadian change and substrate specificity. J Biochem (Tokyo) 91: 755-760, 1982. (Pubitemid 12116983)
224. Kienzl E, Jellinger K, Stachelberger H, and Linert W. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease? Life Sci 65: 1973-1976, 1999. (Pubitemid 29506939)
225. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, and Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10: 402-405, 2004. (Pubitemid 38508519)
226. Kim M, Jung Y, Lee K, and Kim C. Identification of the calcium binding sites in translationally controlled tumor protein. Arch Pharm Res 23: 633-636, 2000.
227. Kim SH, Fountoulakis M, Cairns N, and Lubec G. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl (61): 223-235, 2001. (Pubitemid 38085085)
228. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26: 231-243, 1975.
229. Knyushko TV, Sharov VS, Williams TD, Schoneich C, and Bigelow DJ. 3-Nitrotyrosine modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment. Biochemistry 44: 13071-13081, 2005. (Pubitemid 41377287)
230. Koeppen AH. The history of iron in the brain. J Neurol Sci 134 Suppl: 1-9, 1995.
231. Kondrikov D, Elms S, Fulton D, and Su Y. eNOS-beta-actin interaction contributes to increased peroxynitrite formation during hyperoxia in pulmonary artery endothelial cells and mouse lungs. J Biol Chem 285: 35479-35487, 2010.
232. Korenberg JR, Bradley C, and Disteche CM. Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis. Am J Hum Genet 50: 294-302, 1992.
233. Korolainen MA, Goldsteins G, Alafuzoff I, Koistinaho J, and Pirttila T. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 23: 3428-3433, 2002. (Pubitemid 35230228)
234. Korolainen MA, Goldsteins G, Nyman TA, Alafuzoff I, Koistinaho J, and Pirttila T. Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging 27: 42-53, 2006. (Pubitemid 41627949)
235. LaFontaine MA, Mattson MP, and Butterfield DA. Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease. Neurochem Res 27: 417-421, 2002. (Pubitemid 34579349)
236. Lamprecht R and LeDoux J. Structural plasticity and memory. Nat Rev Neurosci 5: 45-54, 2004. (Pubitemid 38076183)
237. Landino LM, Skreslet TE, and Alston JA. Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J Biol Chem 279: 35101-35105, 2004. (Pubitemid 39318146)
238. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, and Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem 78: 413-416, 2001. (Pubitemid 32664423)
239. Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, and Mayer RJ. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci Lett 209: 57-60, 1996. (Pubitemid 26150420)
240. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, and Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 1: 530-535, 2000.
241. Lee S, Young NL, Whetstone PA, Cheal SM, Benner WH, Lebrilla CB, and Meares CF. Method to site-specifically identify and quantitate carbonyl end products of protein oxidation using oxidation-dependent element coded affinity tags (O-ECAT) and nanoliquid chromatography Fourier transform mass spectrometry. J Prot Res 5: 539-547, 2006. (Pubitemid 43364093)
242. Lee SH, Takahashi R, Goto T, and Oe T. Mass spectrometric characterization of modifications to angiotensin II by lipid peroxidation products, 4-oxo-2(E)-nonenal and 4-hydroxy-2(E)-nonenal. Chem Res Toxicol 23: 1771-1785, 2010.
243. Leigh PN, Whitwell H, Garofalo O, Buller J, Swash M, Martin JE, Gallo JM, Weller RO, and Anderton BH. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 114 (Pt 2): 775-788, 1991.
244. Lemieux N, Malfoy B, and Forrest GL. Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolu-tion fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells. Genomics 15: 169-172, 1993. (Pubitemid 23079585)
245. Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, Pollak P, Durif F, Thobois S, Layet V, Vidailhet M, Agid Y, Durr A, Brice A, Bonnet AM, Borg M, Broussolle E, Damier P, Destee A, Martinez M, Penet C, Rasco O, Tison F, Tranchan C, and Verin M. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 64: 425-430, 2007. (Pubitemid 46425700)
246. Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM, and Hof PR. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 650: 20-31, 1994. (Pubitemid 24207040)
247. Levine RL, Wehr N, Williams JA, Stadtman ER, and Shacter E. Determination of carbonyl groups in oxidized proteins. Methods Mol Biol 99: 15-24, 2000.
248. Li YF, Wang Y, Channon KM, Schultz HD, Zucker IH, and Patel KP. Manipulation of neuronal nitric oxide synthase within the paraventricular nucleus using adenovirus and antisense technology. Methods Mol Med 112: 59-79, 2005.
249. Lillig CH and Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal 9: 25-47, 2007. (Pubitemid 44901873)
250. Lin TK, Hughes G, Muratovska A, Blaikie FH, Brookes PS, Darley-Usmar V, Smith RA, and Murphy MP. Specific modification of mitochondrial protein thiols in response to oxidative stress: a proteomics approach. J Biol Chem 277: 17048-17056, 2002. (Pubitemid 34967734)
251. Liochev SI and Fridovich I. Copper-and zinc-containing superoxide dismutase can act as a superoxide reductase and a superoxide oxidase. J Biol Chem 275: 38482-38485, 2000. (Pubitemid 32009174)
252. Liou YC, Ryo A, Huang HK, Lu PJ, Bronson R, Fujimori F, Uchida T, Hunter T, and Lu KP. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 99: 1335-1340, 2002. (Pubitemid 34136494)
253. Liu D, Wen J, Liu J, and Li L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J 13: 2318-2328, 1999.
254. Liu R, Althaus JS, Ellerbrock BR, Becker DA, and Gurney ME. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 44: 763-770, 1998. (Pubitemid 28516047)
255. Lott IT, Head E, Doran E, and Busciglio J. Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res 3: 521-528, 2006. (Pubitemid 46066428)
256. Lourette N, Smallwood H, Wu S, Robinson EW, Squier TC, Smith RD, and Pasa-Tolic L. A top-down LC-FTICR MSbased strategy for characterizing oxidized calmodulin in activated macrophages. J Am Soc Mass Spectrom 21: 930-939, 2010.
257. Lovell MA, Xie C, Gabbita SP, and Markesbery WR. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med 28: 418-427, 2000. (Pubitemid 30110658)
258. Lovell MA, Xiong S, Markesbery WR, and Lynn BC. Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochem Res 30: 113-122, 2005. (Pubitemid 40254211)
259. Lu B, Motoyama A, Ruse C, Venable J, and Yates JR, 3rd. Improving protein identification sensitivity by combining MS and MS/MS information for shotgun proteomics using LTQ-Orbitrap high mass accuracy data. Anal Chem 80: 2018-2025, 2008. (Pubitemid 351458047)
260. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, and Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl 57: 161-177, 1999.
261. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, and Thompson JA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 93: 11853-11858, 1996. (Pubitemid 26347213)
262. Macmillan-Crow LA and Cruthirds DL. Invited review: manganese superoxide dismutase in disease. Free Radic Res 34: 325-336, 2001. (Pubitemid 32331659)
263. Madian AG and Regnier FE. Proteomic identification of carbonylated proteins and their oxidation sites. J Proteome Res 9: 3766-3780, 2010.
264. Magrane J, Smith RC, Walsh K, and Querfurth HW. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci 24: 1700-1706, 2004. (Pubitemid 38240967)
265. Mandel SA, Fishman-Jacob T, and Youdim MB. Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A. Parkinsonism Relat Disord 15 Suppl 3: S148-S151, 2009.
266. Masliah E, Alford M, DeTeresa R, Mallory M, and Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40: 759-766, 1996. (Pubitemid 26415188)
267. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, and Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 174: 67-72, 1994. (Pubitemid 24205235)
268. Matsuura I, Chiang KN, Lai CY, He D, Wang G, Ramkumar R, Uchida T, Ryo A, Lu K, and Liu F. Pin1 promotes transforming growth factor-beta-induced migration and invasion. J Biol Chem 285: 1754-1764, 2010.
269. Mattson MP, Pedersen WA, Duan W, Culmsee C, and Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci 893: 154-175, 1999. (Pubitemid 30038074)
270. Meier-Ruge W, Bertoni-Freddari C, and Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology 40: 246-252, 1994. (Pubitemid 24221035)
271. Meier-Ruge W, Iwangoff P, and Reichlmeier K. Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Gerontol Geriatr 3: 161-165, 1984. (Pubitemid 14030380)
272. Messier C and Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res 75: 1-11, 1996. (Pubitemid 26076738)
273. Mihm MJ, Schanbacher BL, Wallace BL, Wallace LJ, Uretsky NJ, and Bauer JA. Free 3-nitrotyrosine causes striatal neurodegeneration in vivo. J Neurosci 21: RC149, 2001.
274. Mirzaei H, Baena B, Barbas C, and Regnier F. Identification of oxidized proteins in rat plasma using avidin chromatography and tandem mass spectrometry. Proteomics 8: 1516-1527, 2008. (Pubitemid 351518558)
275. Mirzaei H and Regnier F. Affinity chromatographic selection of carbonylated proteins followed by identification of oxidation sites using tandem mass spectrometry. Anal Chem 77: 2386-2392, 2005. (Pubitemid 40562738)
276. Mirzaei H and Regnier F. Identification and quantification of protein carbonylation using light and heavy isotope labeled Girard's P reagent. J Chromatogr A 1134: 122-133, 2006. (Pubitemid 44633939)
277. Molina JA, de Bustos F, Jimenez-Jimenez FJ, Benito-Leon J, Gasalla T, Orti-Pareja M, Vela L, Bermejo F, Martin MA, Campos Y, and Arenas J. Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. Neurology 48: 636-638, 1997. (Pubitemid 27120098)
278. Montine TJ, Quinn JF, Montine KS, Kaye JA, and Breitner JC. Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. J Alzheimers Dis 8: 359-367, 2005.
279. Morel P, Tallineau C, Pontcharraud R, Piriou A, and Huguet F. Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na +K + ATPase in rat striatal synaptosomes. Neurochem Int 33: 531-540, 1998. (Pubitemid 29116229)
280. Mouser PE, Head E, Ha KH, and Rohn TT. Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol 168: 936-946, 2006. (Pubitemid 43327746)
281. Muller WE, Eckert A, Kurz C, Eckert GP, and Leuner K. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease-therapeutic aspects. Mol Neurobiol 41: 159-171, 2010.
282. Nagy Z, Esiri MM, Cato AM, and Smith AD. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol 94: 6-15, 1997. (Pubitemid 27289096)
283. Nakamura A and Goto S. Analysis of protein carbonyls with 2,4-dinitrophenyl hydrazine and its antibodies by immunoblot in two-dimensional gel electrophoresis. J Biochem 119: 768-774, 1996. (Pubitemid 26135151)
284. Neely MD, Boutte A, Milatovic D, and Montine TJ. Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction. Brain Res 1037: 90-98, 2005. (Pubitemid 40362384)
285. Niatsetskaya Z, Basso M, Speer RE, McConoughey SJ, Coppola G, Ma TC, and Ratan RR. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 12: 435-443, 2010.
286. Nikov G, Bhat V, Wishnok JS, and Tannenbaum SR. Analysis of nitrated proteins by nitrotyrosine-specific affinity probes and mass spectrometry. Anal Biochem 320: 214-222, 2003. (Pubitemid 36962845)
287. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, and Yodoi J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650, 1999.
288. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, and Smith MA. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59: 1011-1017, 2000.
289. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250: 4007-4021, 1975.
290. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F, Piombo G, Perry G, Smith M, Traverso N, and Tabaton M. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 243: 849-851, 1998. (Pubitemid 28414171)
291. Ojika K, Tsugu Y, Mitake S, Otsuka Y, and Katada E. NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro. Brain Res Dev Brain Res 106: 173-180, 1998. (Pubitemid 28168483)
292. Oka S, Masutani H, Liu W, Horita H, Wang D, Kizaka-Kondoh S, and Yodoi J. Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Endocrinology 147: 733-743, 2006. (Pubitemid 43112989)
293. Op den Velde W and Stam FC. Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia. J Am Geriatr Soc 24: 12-16, 1976.
294. Orrenius S, Burgess DH, Hampton MB, and Zhivotovsky B. Mitochondria as the focus of apoptosis research. Cell Death Differ 4: 427-428, 1997.
295. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, and Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20: 6048-6054, 2000. (Pubitemid 30658398)
296. Ou J, Fontana JT, Ou Z, Jones DW, Ackerman AW, Oldham KT, Yu J, Sessa WC, and Pritchard KA, Jr. Heat shock protein 90 and tyrosine kinase regulate eNOS NO* generation but not NO* bioactivity. Am J Physiol Heart Circ Physiol 286: H561-H569, 2004. (Pubitemid 38140336)
297. Owen JB, Sultana R, Aluise CD, Erickson MA, Price TO, Bu G, Banks WA, and Butterfield DA. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain. Free Radic Biol Med 49: 1798-1803, 2010.
298. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279: 18614-18622, 2004. (Pubitemid 38623283)
299. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, and Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5: 731-736, 2002. (Pubitemid 34827590)
300. Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, and Grundke-Iqbal I. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res 109: 45-55, 2002. (Pubitemid 36078372)
301. Perluigi M, di Domenico F, Fiorini A, Cocciolo A, Giorgi A, Foppoli C, Butterfield DA, Giorlandino M, Giorlandino C, Schinina ME, and Coccia R. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Prot Clin Appl 5: 167-178, 2011.
302. Perluigi M, Fai Poon H, Hensley K, Pierce WM, Klein JB, Calabrese V, De Marco C, and Butterfield DA. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 38: 960-968, 2005. (Pubitemid 40321087)
303. Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, Cini C, De Marco C, and Butterfield DA. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics 4: 1849-1861, 2005. (Pubitemid 41830180)
304. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, and Butterfield DA. Redox proteomics identification of HNE-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 3: 682-693, 2009.
305. Perumal AS, Tordzro WK, Katz M, Jackson-Lewis V, Cooper TB, Fahn S, and Cadet JL. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain. Brain Res 504: 139-141, 1989. (Pubitemid 20014053)
306. Pestova TV and Hellen CU. The structure and function of initiation factors in eukaryotic protein synthesis. Cell Mol Life Sci 57: 651-674, 2000. (Pubitemid 30311435)
307. Petersen A, Hansson O, Puschban Z, Sapp E, Romero N, Castilho RF, Sulzer D, Rice M, DiFiglia M, Przedborski S, and Brundin P. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur J Neurosci 14: 1425-1435, 2001. (Pubitemid 35463710)
308. Petronis A. Alzheimer's disease and down syndrome: from meiosis to dementia. Exp Neurol 158: 403-413, 1999. (Pubitemid 29382830)
309. Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, and Muenz LR. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging 15: 117-132, 1994. (Pubitemid 24075020)
310. Picklo MJ, Montine TJ, Amarnath V, and Neely MD. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 184: 187-197, 2002. (Pubitemid 35428851)
311. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, and Takashima A. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci 24: 2401-2411, 2004. (Pubitemid 38327953)
312. Pocernich CB, Lange ML, Sultana R, and Butterfield DA. Nutritional approaches to modulate oxidative stress in Alzheimer's disease. Curr Alzheimer Res 8: 452-469, 2011.
313. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, and Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol Dis 18: 492-498, 2005. (Pubitemid 40332708)
314. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, Klein JB, Calabrese V, and Butterfield DA. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 39: 453-462, 2005. (Pubitemid 41021644)
315. Rakhit R, Cunningham P, Furtos-Matei A, Dahan S, Qi XF, Crow JP, Cashman NR, Kondejewski LH, and Chakrabartty A. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem 277: 47551-47556, 2002. (Pubitemid 36159274)
316. Ramakrishnan P, Dickson DW, and Davies P. Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. Neurobiol Dis 14: 251-264, 2003.
317. Rapoport SI. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249 Suppl 3: 46-55, 1999.
318. Rauniyar N and Prokai L. Detection and identification of 4-hydroxy-2-nonenal Schiff-base adducts along with products of Michael addition using data-dependent neutral lossdriven MS3 acquisition: method evaluation through an in vitro study on cytochrome c oxidase modifications. Proteomics 9: 5188-5193, 2009.
319. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH, Jr., Scott RW, and Snider WD. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 13: 43-47, 1996. (Pubitemid 26139292)
320. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, and Butterfield DA. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 30: 107-120, 2008.
321. Reed TT, Pierce WM, Jr., Turner DM, Markesbery WR, and Butterfield DA. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med 13: 2019-2029, 2009.
322. Reed TT, Pierce WM, Markesbery WR, and Butterfield DA. Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274: 66-76, 2009.
323. Reiner M, Bloch W, and Addicks K. Functional interaction of caveolin-1 and eNOS in myocardial capillary endothelium revealed by immunoelectron microscopy. J Histochem Cytochem 49: 1605-1610, 2001.
324. Rhee SG, Chae HZ, and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005. (Pubitemid 40726061)
325. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, and Youdim MB. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520, 1989. (Pubitemid 19037617)
326. Riviere S, Birlouez-Aragon I, Nourhashemi F, and Vellas B. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry 13: 749-754, 1998. (Pubitemid 28542706)
327. Roe MR, McGowan TF, Thompson LV, and Griffin TJ. Targeted 18O-labeling for improved proteomic analysis of carbonylated peptides by mass spectrometry. J Am Soc Mass Spectrom 21: 1190-1203, 2010.
328. Rossor MN, Iversen LL, Johnson AJ, Mountjoy CQ, and Roth M. Cholinergic deficit in frontal cerebral cortex in Alzheimer's disease is age dependent. Lancet 2: 1422, 1981.
329. Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, Harada T, Ichihara N, Wakana S, Kikuchi T, and Wada K. Intragenic deletion in the gene encoding ubiquitin carboxyterminal hydrolase in gad mice. Nat Genet 23: 47-51, 1999. (Pubitemid 29418786)
330. Sajdel-Sulkowska EM and Marotta CA. Alzheimer's disease brain: alterations in RNA levels and in a ribonucleaseinhibitor complex. Science 225: 947-949, 1984. (Pubitemid 14064179)
331. Salmon M, Dedessus Le Moutier J, Wenders F, Chiarizia S, Eliaers F, Remacle J, Royer V, Pascal T, and Toussaint O. Role of the PLA2-independent peroxiredoxin VI activity in the survival of immortalized fibroblasts exposed to cytotoxic oxidative stress. FEBS Lett 557: 26-32, 2004. (Pubitemid 38115864)
332. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, and Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68: 2092-2097, 1997. (Pubitemid 27176147)
333. Schapira AH. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta 1410: 159-170, 1999. (Pubitemid 29078602)
334. Scheff SW and Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 24: 1029-1046, 2003. (Pubitemid 37487881)
335. Scheff SW and Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 9: 101-115, 2006. (Pubitemid 44253303)
336. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, and Borchelt DR. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8: 397-407, 1999. (Pubitemid 29097327)
337. Schneider C, Porter NA, and Brash AR. Autoxidative transformation of chiral omega6 hydroxy linoleic and arachidonic acids to chiral 4-hydroxy-2E-nonenal. Chem Res Toxicol 17: 937-941, 2004. (Pubitemid 38955353)
338. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, and Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279: 30369-30374, 2004. (Pubitemid 38937964)
339. Schutkowski M, Bernhardt A, Zhou XZ, Shen M, Reimer U, Rahfeld JU, Lu KP, and Fischer G. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry 37: 5566-5575, 1998. (Pubitemid 28241940)
340. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766, 2001. (Pubitemid 32267077)
341. Sergeant N, Wattez A, Galvan-valencia M, Ghestem A, David JP, Lemoine J, Sautiere PE, Dachary J, Mazat JP, Michalski JC, Velours J, Mena-Lopez R, and Delacourte A. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neurosci 117: 293-303, 2003. (Pubitemid 36259745)
342. Shaw PJ, Ince PG, Falkous G, and Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 38: 691-695, 1995.
343. Sherer TB, Betarbet R, and Greenamyre JT. Environment, mitochondria, and Parkinson's disease. Neuroscientist 8: 192-197, 2002. (Pubitemid 34538786)
344. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S, and Kobayashi M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917: 97-104, 2001. (Pubitemid 32972133)
345. Shinder GA, Lacourse MC, Minotti S, and Durham HD. Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J Biol Chem 276: 12791-12796, 2001.
346. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, and Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550, 2002.
347. Siciliano G, Piazza S, Carlesi C, Del Corona A, Franzini M, Pompella A, Malvaldi G, Mancuso M, Paolicchi A, and Murri L. Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. J Neurol 254: 575-580, 2007. (Pubitemid 46781962)
348. Siems WG, Hapner SJ, and van Kuijk FJ. 4-hydroxynonenal inhibits Na( + )-K( + )-ATPase. Free Radic Biol Med 20: 215-223, 1996.
349. Simmons DA, Casale M, Alcon B, Pham N, Narayan N, and Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 55: 1074-1084, 2007. (Pubitemid 47066747)
350. Singh AK, Gupta S, and Jiang Y. Oxidative stress and protein oxidation in the brain of water drinking and alcohol drinking rats administered the HIV envelope protein, gp120. J Neurochem 104: 1478-1493, 2008. (Pubitemid 351316762)
351. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, and Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 80: 2752-2756, 1983. (Pubitemid 13093387)
352. Smith CD, Carney JM, Starkereed PE, Oliver CN, Stadtman ER, Floyd RA, and Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer-disease. Proc Natl Acad Sci USA 88: 10540-10543, 1991. (Pubitemid 21915871)
353. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, and Perry G. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4- dinitrophenylhydrazine. J Histochem Cytochem 46: 731-735, 1998. (Pubitemid 28272207)
354. Smith PJ, Tappel AL, and Chow CK. Glutathione peroxidase activity as a function of dietary selenomethionine. Nature 247: 392-393, 1974.
355. Smith RG, Henry YK, Mattson MP, and Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44: 696-699, 1998. (Pubitemid 28477861)
356. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS, and Shaw DJ. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 4: 393-397, 1993. (Pubitemid 23231489)
357. Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, and Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45: 667-678, 2008.
358. Sousa LP, Silva BM, Brasil BS, Nogueira SV, Ferreira PC, Kroon EG, Kato K, and Bonjardim CA. Plasminogen/plasmin regulates alpha-enolase expression through the MEK/ERK pathway. Biochem Biophys Res Commun 337: 1065-1071, 2005. (Pubitemid 41505234)
359. Sperandio S, Poksay KS, Schilling B, Crippen D, Gibson BW, and Bredesen DE. Identification of new modulators and protein alterations in non-apoptotic programmed cell death. J Cell Biochem 111: 1401-1412, 2010.
360. Stadtman ER and Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 25: 207-218, 2003. (Pubitemid 38043943)
361. Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, and Butterfield DA. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 69: 1161-1169, 1997. (Pubitemid 27364837)
362. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, and Butterfield DA. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11: 153-164, 2007. (Pubitemid 47010980)
363. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, and Butterfield DA. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27: 1564-1576, 2006. (Pubitemid 44344840)
364. Sultana R and Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem Res 29: 2215-2220, 2004. (Pubitemid 40036893)
365. Sultana R and Butterfield DA. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr 41: 441-446, 2009.
366. Sultana R and Butterfield DA. Identification of the oxidative stress proteome in the brain. Free Radic Biol Med 50: 487-494, 2011.
367. Sultana R, Mecocci P, Mangialasche F, Cecchetti R, Baglioni M, and Butterfield DA. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis 24: 77-84, 2011.
368. Sultana R, Perluigi M, and Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 8: 2021-2037, 2006. (Pubitemid 46499264)
369. Sultana R, Perluigi M, and Butterfield DA. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118: 131-150, 2009.
370. Sultana R, Perluigi M, Newman SF, Pierce WM, Cini C, Coccia R, and Butterfield DA. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxid Redox Signal 12: 327-336, 2010.
371. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, and Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22: 76-87, 2006.
372. Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, and Butterfield DA. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med 11: 839-851, 2007. (Pubitemid 47313301)
373. Surmeli NB, Litterman NK, Miller AF, and Groves JT. Peroxynitrite mediates active site tyrosine nitration in manganese superoxide dismutase. Evidence of a role for the carbonate radical anion. J Am Chem Soc 132: 17174-17185, 2010.
374. Suzuki YJ, Carini M, and Butterfield DA. Protein carbonylation. Antioxid Redox Signal 12: 323-325, 2010.
375. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 140-141: 105-112, 2003. (Pubitemid 36378928)
376. Tamarit J, Cabiscol E, and Ros J. Identification of the major oxidatively damaged proteins in Escherichia coli cells exposed to oxidative stress. J Biol Chem 273: 3027-3032, 1998. (Pubitemid 28133956)
377. Temple A, Yen TY, and Gronert S. Identification of specific protein carbonylation sites in model oxidations of human serum albumin. J Am Soc Mass Spectrom 17: 1172-1180, 2006. (Pubitemid 44094131)
378. Thaw P, Baxter NJ, Hounslow AM, Price C, Waltho JP, and Craven CJ. Structure of TCTP reveals unexpected relationship with guanine nucleotide-free chaperones. Nat Struct Biol 8: 701-704, 2001. (Pubitemid 32757930)
379. Thompson JE, Hopkins MT, Taylor C, and Wang TW. Regulation of senescence by eukaryotic translation initiation factor 5A: implications for plant growth and development. Trends Plant Sci 9: 174-179, 2004. (Pubitemid 38448756)
380. Thompson KJ, Shoham S, and Connor JR. Iron and neurodegenerative disorders. Brain Res Bull 55: 155-164, 2001. (Pubitemid 32722155)
381. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, and MacDonald ME. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9: 2799-2809, 2000.
382. Trujillo M, Folkes L, Bartesaghi S, Kalyanaraman B, Wardman P, and Radi R. Peroxynitrite-derived carbonate and nitrogen dioxide radicals readily react with lipoic and dihydrolipoic acid. Free Radic Biol Med 39: 279-288, 2005. (Pubitemid 40814553)
383. Tsujimoto KH, Kawai T, Matsumoto H. Oxidized protein quantitation method using isotope-substituted labeling reagent and mass spectrometry. pp 2007-JP55617 2007111193, 2020070320.
384. Uchida K and Stadtman ER. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra-and intermolecular cross-linking reaction. J Biol Chem 268: 6388-6393, 1993. (Pubitemid 23099334)
385. Valencia CA, Ju W, and Liu R. Matrin 3 is a Ca2 +calmodulin-binding protein cleaved by caspases. Biochem Biophys Res Commun 361: 281-286, 2007. (Pubitemid 47187255)
386. Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, and Bentivoglio AR. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 56: 336-341, 2004. (Pubitemid 39166552)
387. Valentine JS. Do oxidatively modified proteins cause ALS? Free Radic Biol Med 33: 1314-1320, 2002. (Pubitemid 35284916)
388. Van Laar VS, Dukes AA, Cascio M, and Hastings TG. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis 29: 477-489, 2008.
389. Vana L, Kanaan NM, Hakala K, Weintraub ST, and Binder LI. Peroxynitrite-induced nitrative and oxidative modifications alter tau filament formation. Biochemistry 50: 1203-1212, 2011.
390. Vayssiere JL, Cordeau-Lossouarn L, Larcher JC, Basseville M, Gros F, and Croizat B. Participation of the mitochondrial genome in the differentiation of neuroblastoma cells. In Vitro Cell Dev Biol 28A: 763-772, 1992. (Pubitemid 23054050)
391. Vexler ZS, Wong A, Francisco C, Manabat C, Christen S, Tauber M, Ferriero DM, and Gregory G. Fructose-1,6-bisphosphate preserves intracellular glutathione and protects cortical neurons against oxidative stress. Brain Res 960: 90-98, 2003. (Pubitemid 36044566)
392. Vila A, Tallman KA, Jacobs AT, Liebler DC, Porter NA, and Marnett LJ. Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. Chem Res Toxicol 21: 432-444, 2008.
393. Viner RI, Ferrington DA, Williams TD, Bigelow DJ, and Schoneich C. Protein modification during biological aging: selective tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2 +-ATPase in skeletal muscle. Biochem J 340 (Pt 3): 657-669, 1999. (Pubitemid 29312862)
394. Wallimann T and Hemmer W. Creatine kinase in nonmuscle tissues and cells. Mol Cell Biochem 133-134: 193-220, 1994. (Pubitemid 24276833)
395. Wang J, Xu G, Gonzales V, Coonfield M, Fromholt D, Copeland NG, Jenkins NA, and Borchelt DR. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol Dis 10: 128-138, 2002. (Pubitemid 34775466)
396. Wang X, Moualla D, Wright JA, and Brown DR. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J Neurochem 113: 704-714, 2010.
397. Wang XS, Lee S, Simmons Z, Boyer P, Scott K, Liu W, and Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci 227: 27-33, 2004. (Pubitemid 39491122)
398. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, and Rothstein JD. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8: 933-941, 2001. (Pubitemid 34017087)
399. Weitzdoerfer R, Fountoulakis M, and Lubec G. Aberrant expression of dihydropyrimidinase related proteins-2,-3 and 4 in fetal Down syndrome brain. J Neural Transm Suppl 61:95-107, 2001. (Pubitemid 38085075)
400. Winklhofer KF. The parkin protein as a therapeutic target in Parkinson's disease. Expert Opin Ther Targets 11: 1543-1552, 2007. (Pubitemid 350285004)
401. Winterbourn CC and Buss IH. Protein carbonyl measurement by enzyme-linked immunosorbent assay. Methods Enzymol 300: 106-111, 1999.
402. Yamakura F, Matsumoto T, Fujimura T, Taka H, Murayama K, Imai T, and Uchida K. Modification of a single tryptophan residue in human Cu,Zn-superoxide dismutase by peroxynitrite in the presence of bicarbonate. Biochim Biophys Acta 1548: 38-46, 2001. (Pubitemid 32622818)
403. Yamashiro S, Yamakita Y, Ono S, and Matsumura F. Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol Biol Cell 9: 993-1006, 1998. (Pubitemid 28457295)
404. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, and Beal MF. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 109: 1427-1439, 2009.
405. YarianCS,RebrinI, andSohalRS.Aconitase andATPsynthase are targets of malondialdehyde modification and undergo an age-related decrease in activity in mouse heart mitochondria. Biochem Biophys Res Commun 330: 151-156, 2005. (Pubitemid 40394947)
406. Yoo BS and Regnier FE. Proteomic analysis of carbonylated proteins in two-dimensional gel electrophoresis using avidin-fluorescein affinity staining. Electrophoresis 25: 1334-1341, 2004. (Pubitemid 38801652)
407. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, and Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93: 2696-2701, 1996. (Pubitemid 26114311)
408. Yoshida H, Watanabe A, and Ihara Y. Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. J Biol Chem 273: 9761-9768, 1998. (Pubitemid 28183069)
409. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, and Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11: 155-163, 1995.
410. Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, and Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59: 1161-1169, 2002. (Pubitemid 35192385)
411. Zhou J, Yu Q, and Chng WJ. TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int J Biochem Cell Biol 43: 1668-1673, 2011.
412. Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, Kullertz G, Stark M, Fischer G, and Lu KP. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 6: 873-883, 2000.